Research And Development
Health
Pharmaceutical
Array BioPharma
$26.279876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$26.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.85 (3.33%) Today
-$0.13 (-0.49%) After Hours
Why Robinhood?
You can buy or sell ARRY and other stocks, options, ETFs, and crypto commission-free!
About
Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. Read More The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.
CEO
Employees
298
Headquarters
Boulder, Colorado
Founded
1998
Market Cap
5.66B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.80M
High Today
$26.51
Low Today
$25.20
Open Price
$25.70
Volume
3.07M
52 Week High
$26.82
52 Week Low
$12.56
Collections
Research And Development
Health
Pharmaceutical
Cancer Prevention
Biotechnology
Technology
News
BenzingaMay 16
Why Array BioPharma Shares Fell Thursday
Pharmaceutical company Array BioPharma Inc. (NASDAQ: ARRY) shares dipped more than 3 percent Thursday following comments from a sell-side analyst that investors may have to wait longer for results from Array's BeaconCRC colon cancer study. The results were expected to be presented at the American Society of Clinical Oncology meeting later this month, but the late-breaking abstract no longer appears on the conference's program, a Bloomberg reporter tweeted Thursdasy. Michelle Fay Cortez said the abstract w...
Seeking AlphaMay 7
Array BioPharma Inc. (ARRY) CEO Ron Squarer on Q3 2019 Results - Earnings Call Transcript
Array BioPharma Inc. (NASDAQ:ARRY) Q3 2019 Earnings Conference Call May 7, 2019 9:00 AM ET Company Participants Andrea Flynn - Senior Director of Investor Relations & Corporate Communications Ron Squarer - Chief Executive Officer Andy Robbins - Chief Operating Officer Jason Haddock - Chief Financial Officer Conference Call Participants Chris Shibutani - Cowen Anupam Rama - JPMorgan Stephen Willey - Stifel Peter Lawson - SunTrust Michael Schmidt - Guggenheim Jim Birchenough - Wells Fargo Eun Yan...
Markets InsiderMay 7
EARNINGS SUMMARY: Details of Array BioPharma Inc. Q3 Earnings Report
(RTTNews) - Below are the earnings highlights for Array BioPharma Inc. (ARRY): -Earnings: -$37.49 million in Q3 vs. -$22.85 million in the same period last year. -EPS: -$0.17 in Q3 vs. -$0.11 in the same period last year. -Analysts projected -$0.20 per share -Revenue: $64.68 million in Q3 vs. $66.37 million in the same period last year....
Price Paid on Robinhood
58% Higher
Right Now
52 Week Low
$12.56
Average Price Paid
$16.67
52 Week High
$26.82
Earnings
-$0.25
-$0.18
-$0.12
-$0.05
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Aug 13, Pre-Market